| 000 | 01597 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250512081055.0 | ||
| 264 | 0 | _c19860116 | |
| 008 | 198601s 0 0 eng d | ||
| 022 | _a0364-5134 | ||
| 024 | 7 |
_a10.1002/ana.410180506 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSnyder, A M | |
| 245 | 0 | 0 |
_aStress-induced neurological impairments in an animal model of parkinsonism. _h[electronic resource] |
| 260 |
_bAnnals of neurology _cNov 1985 |
||
| 300 |
_a544-51 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aBupropion |
| 650 | 0 | 4 |
_aCorpus Striatum _xdrug effects |
| 650 | 0 | 4 |
_aDeoxyglucose _xpharmacology |
| 650 | 0 | 4 |
_aDesipramine _xpharmacology |
| 650 | 0 | 4 |
_aDopamine _xmetabolism |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aHydroxydopamines _xpharmacology |
| 650 | 0 | 4 | _aInjections, Intraventricular |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aNeural Pathways _xdrug effects |
| 650 | 0 | 4 |
_aNorepinephrine _xmetabolism |
| 650 | 0 | 4 | _aOxidopamine |
| 650 | 0 | 4 |
_aPargyline _xpharmacology |
| 650 | 0 | 4 |
_aParkinson Disease, Secondary _xchemically induced |
| 650 | 0 | 4 |
_aPropiophenones _xpharmacology |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Inbred Strains |
| 650 | 0 | 4 |
_aReceptors, Dopamine _xdrug effects |
| 650 | 0 | 4 |
_aStress, Physiological _xcomplications |
| 700 | 1 | _aStricker, E M | |
| 700 | 1 | _aZigmond, M J | |
| 773 | 0 |
_tAnnals of neurology _gvol. 18 _gno. 5 _gp. 544-51 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/ana.410180506 _zAvailable from publisher's website |
| 999 |
_c3940726 _d3940726 |
||